Analysis of Oncogene-induced-Senescence related genes in cancer for clinical application

• Project/Area Number: 23591986
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Digestive surgery
• Research Institution: Nagoya University
• Principal Investigator: IGAMI TSUYOSHI 名古屋大学, 医学部附属病院, 病院講師 (50420378)
• Co-Investigator(Kenkyū-buntansha): NAGINO Masato 名古屋大学, 医学系研究科, 教授 (20237564) ; YOKOYAMA Yukihiro 名古屋大学, 医学部附属病院, 講師 (80378091) ; KOKURYO Toshio 名古屋大学, 医学系研究科, 特任講師 (60378023)
• Project Period (FY): 2011 – 2013
• Project Status: Completed (Fiscal Year 2013)
• Budget Amount: ¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000); Fiscal Year 2013: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000); Fiscal Year 2012: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000); Fiscal Year 2011: ¥2,730,000 (Direct Cost: ¥2,100,000、Indirect Cost: ¥630,000)
• Keywords: Senescence / HJURP

Research Abstract

Senescence is the irreversible cell cycle arrest for the shortage of telomea. We identified gene HJURP (Holliday junction recognition protein) as Oncogene induced Senescence connection gene. HJURP is one kind of the histone chaperon. HJURP is highly expressed in human cholangiocarcinoma cell strain and pancreatic cancer cell strain. HJURP siRNA suppressed the cell proliferation in cholangiocarcinoma cell strain. In addition, we examined the combination treatment of anticancer agent CDDP and HJURP siRNA. The cell proliferation was inhibited in HJURP siRNA2 group, compared to control siRNA group. HJURP siRNA2 enhanced the effect of anticancer agent CDDP.
Next, the prognosis is poor in the overexpression group of HJURP in cholangiocarcinoma and pancreatic cancer. Our data suggested that HJURP may be a prognostic prediction marker in the pancreatic cancer and cholangiocarcinoma.